Intercept Hopes Statin Trial Will Lessen Ocaliva's Perceived CV Risk

After otherwise successful Phase II NASH trial showed Ocaliva can increase a patient's LDL cholesterol levels, Intercept hopes a study in NASH patients who use atorvastatin will show this effect is manageable.